ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer.
ABO blood type
long-term outcomes
pancreatic cancer
tumor behavior
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
17
3
2020
pubmed:
17
3
2020
medline:
10
6
2020
Statut:
ppublish
Résumé
Objective The long-term effect of the ABO blood type on the clinical course of patients with pancreatic cancer (PC) is inconclusive. This study aimed to determine whether or not the ABO blood type influences the long-term outcomes of PC in Japanese patients. Methods The medical records of Japanese patients with PC were reviewed. Data, including the age, sex, and outcomes, from the Ehime Pancreato-Cholangiology Study Group were analyzed. Results The mean age of the 406 patients was 71.0±10.5 years, and 220 (54.2%) were men. A total of 44.6%, 20.7%, 22.4%, and 12.3% had blood type A, B, O, and AB, respectively. The median survival time (MST) of patients with A alleles was shorter than that of patients with non-A alleles (p=0.048), especially among those who underwent resection (p=0.031). In contrast, no marked difference in the MST was noted among those who underwent chemotherapy and palliative care. Finally, a multivariate analysis confirmed A alleles as an independent factor associated with the long-term outcome of PC (p<0.05 in 2 different models). Conclusion The ABO blood type influenced the long-term outcomes of Japanese patients with PC, presumably due to its impact on disease onset and tumor behavior.
Identifiants
pubmed: 32173688
doi: 10.2169/internalmedicine.3748-19
pmc: PMC7118372
doi:
Substances chimiques
ABO Blood-Group System
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
761-768Références
J Natl Cancer Inst. 2009 Mar 18;101(6):424-31
pubmed: 19276450
BMC Gastroenterol. 2013 Aug 31;13:134
pubmed: 24256464
Int J Cancer. 1991 Jan 21;47(2):180-7
pubmed: 1988363
Br J Cancer. 2014 Jul 8;111(1):174-80
pubmed: 24901236
Cancer Detect Prev Suppl. 1987;1:145-8
pubmed: 3319143
PLoS One. 2012;7(7):e41984
pubmed: 22911869
Tumour Biol. 2014 Jul;35(7):7201-8
pubmed: 24771222
Int J Cancer. 2011 Mar 1;128(5):1179-86
pubmed: 20473916
Asian Pac J Cancer Prev. 2012;13(12):6151-3
pubmed: 23464421
Cancer Res. 1988 Oct 1;48(19):5422-6
pubmed: 3166398
J Urol. 2014 May;191(5):1238-43
pubmed: 24333243
J Biol Chem. 2001 Nov 9;276(45):41527-42
pubmed: 11553646
J Natl Cancer Inst. 1987 Sep;79(3):425-34
pubmed: 2442445
J Clin Oncol. 2016 Jun 10;34(17):2010-9
pubmed: 27114589
Glycobiology. 2002 Dec;12(12):851-6
pubmed: 12499407
PLoS One. 2013 Aug 06;8(8):e71367
pubmed: 23940742
BJU Int. 2012 Dec;110(11 Pt B):E641-6
pubmed: 22958439
Cancer Med. 2017 Jul;6(7):1531-1540
pubmed: 28556564
BMC Cancer. 2012 Jul 28;12:319
pubmed: 22838843
Nat Genet. 2009 Sep;41(9):986-90
pubmed: 19648918
Gut. 2013 Mar;62(3):339-47
pubmed: 23135763
Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1665-72
pubmed: 21680535
Biochim Biophys Acta. 1999 Dec 6;1473(1):247-66
pubmed: 10580143
Cancer Sci. 2011 May;102(5):1076-80
pubmed: 21306478